Cytokinetics Investor Breakfast  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Mar 31 Calls Today's Calls

Call Details Cytokinetics Investor Breakfast Mon, Mar 31, 2008, 8:00 am Eastern Listen to the archived event audio About Cytokinetics, Inc. (NasdaqGM:CYTK) Other Calls  Cytokinetics, Incorporated, a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s products include CK-1827452, a cardiac myosin activator for the potential treatment of heart failure in Phase I and Phase IIa trials; Ispinesib, a cancer drug candidate in Phase II clinical trial to treat multiple tumor types, including breast, ovarian, renal cell, prostate, hepatocellular, melanoma, head and neck, colorectal, and nonsmall cell lung cancer; SB-743921 in Phase I/II clinical trials for the treatment of cancer; and GSK-923295 in Phase I clinical trial designed to investigate the safety, tolerability, pharmacodynamics, and pharmacokinetic profile in patients with solid tumor. It has a strategic alliance with Amgen, Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295. The company was founded in 1997 and is headquartered in South San Francisco, California. More Info: Quote | Chart | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings